English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background  This therapeutic drug monitoring (TDM) study aimed to determine the role of olanzapine (OLZ) and  N -desmethyl-OLZ (DMO) levels in the therapeutic efficacy of OLZ in patients with schizophrenia.    Method  Plasma concentrations of OLZ (C OLZ ) and DMO (C DMO ) in schizophrenic patients 12 hours post-dose were assessed. The correlations of C OLZ  and C DMO  with the various scores of the Positive and Negative Syndrome Scale (PANSS) were evaluated. A receiver operating characteristic curve (ROC) was utilized to identify the threshold C OLZ  and C OLZ /C DMO  ratio for maintenance of satisfactory efficacy.    Results  A total of 151 samples from patients with schizophrenia were analyzed for individual C OLZ  and C DMO  levels. The mean C OLZ  and C DMO  levels were 37.0 ± 25.6 and 6.9 ± 4.7 ng/mL, respectively, and C OLZ  was ~50% higher in female or nonsmokers (p<0.01). In all patients, the daily dose of OLZ was positively correlated with C OLZ  and C DMO . Linear relationships between C OLZ  and OLZ dose were observed in both nonsmokers and smokers (r s  = 0.306, 0.426, p<0.01), although C DMO  was only correlated with OLZ dose in smokers (r s  = 0.485, p<0.01) and not nonsmokers. In all patients, C OLZ  was marginally negatively correlated with the total PANSS score. The total PANSS score was significantly negatively correlated with the C OLZ /C DMO  ratio (p<0.005), except in smokers. The ROC analysis identified a C OLZ /C DMO  ratio ≥2.99 or C OLZ  ≥22.77 ng/mL as a predictor of maintenance of an at least mildly ill status (PANSS score ≤58) of schizophrenia in all patients.    Conclusions  A significantly negative correlation between the steady-state C OLZ /C DMO  ratio and total PANSS score was observed in Taiwanese schizophrenic patients. TDM of both OLZ and DMO levels could assist clinical practice when individualizing OLZ dosage adjustments for patients with schizophrenia.

Application of Plasma Levels of Olanzapine and N-Desmethyl-Olanzapine to Monitor Clinical Efficacy in Patients with Schizophrenia